Abstract
2532Background: “Drug development of targeted agent associations is a challenge”. Previous traditional industry phase I trials failed to define the tolerable dose/dosing schedules of EVE & SOR comb...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
